Avanza Fonder AB Purchases 6,999 Shares of Zoetis Inc. $ZTS

Avanza Fonder AB lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 14.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 55,728 shares of the company’s stock after buying an additional 6,999 shares during the quarter. Avanza Fonder AB’s holdings in Zoetis were worth $7,012,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. North Star Asset Management Inc. boosted its position in Zoetis by 4.9% during the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after acquiring an additional 67 shares during the last quarter. Bank of Nova Scotia Trust Co. grew its holdings in Zoetis by 4.6% during the 2nd quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock worth $264,000 after acquiring an additional 74 shares during the period. Summit Place Financial Advisors LLC raised its position in shares of Zoetis by 0.4% in the 3rd quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock worth $2,834,000 after acquiring an additional 76 shares in the last quarter. First County Bank CT lifted its stake in shares of Zoetis by 5.4% in the 3rd quarter. First County Bank CT now owns 1,535 shares of the company’s stock valued at $225,000 after purchasing an additional 79 shares during the period. Finally, CWA Asset Management Group LLC lifted its stake in shares of Zoetis by 1.1% in the 3rd quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock valued at $1,059,000 after purchasing an additional 80 shares during the period. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of several recent analyst reports. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Piper Sandler reissued a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Morgan Stanley set a $160.00 price target on Zoetis in a report on Thursday, December 18th. BTIG Research reaffirmed a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Finally, The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Stock Performance

Shares of Zoetis stock opened at $115.31 on Tuesday. The business has a 50-day simple moving average of $124.15 and a 200 day simple moving average of $130.02. Zoetis Inc. has a one year low of $114.36 and a one year high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a market capitalization of $48.68 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 1.77 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the prior year, the company earned $1.40 earnings per share. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.